Arthur E. Frankel

6.9k citations
144 papers · 5.2k · 3 hit papers · h-index 40

Impact in

  • Biotechnology top 0.2%
    • Transgenic Plants and Applications
  • Immunology top 0.5%
    • Toxin Mechanisms and Immunotoxins
    • Immunotherapy and Immune Responses

Papers in

    • Toxin Mechanisms and Immunotoxins 82
    • Transgenic Plants and Applications 40
    • Cancer Research and Treatments 20
    • Microbial Inactivation Methods 11

Arthur E. Frankel

143 papers receiving 5.1k citations

Arthur E. Frankel's Hit Papers

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors 2021 · 192 citations
1920+3+6Years since publication250500750

Peers

Arthur E. Frankel
Comparison fields: 5 of 117
  • Biotechnology 1.3k
  • Immunology 2.5k
  • Oncology 1.4k
  • Molecular Biology 2.6k
  • Cancer Research 495
Replace Frank Podlaski with:
Frank Podlaski United States
Arthur E. Frankel United States
Daisy Carvajal United States
Victor S. Goldmacher United States
E S Vitetta United States
Sunil Chada United States
Antoine Tesnière France
Bernard Sordat Switzerland
David Fitzgerald United States
J W Uhr United States
Arthur E. Frankel relative to Frank Podlaski United States Frank Podlaski's profile →
Citations per field
00.5×2.6×
Frank Podlaski · 1×
Citations per year

Countries citing papers authored by Arthur E. Frankel

Since Specialization
Citations

This map shows the geographic impact of Arthur E. Frankel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur E. Frankel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur E. Frankel more than expected).

Fields of papers citing papers by Arthur E. Frankel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur E. Frankel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur E. Frankel. The network helps show where Arthur E. Frankel may publish in the future.

Co-authors

The 25 scholars most cited alongside Arthur E. Frankel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Arthur E. Frankel Line = papers co-authored together Arthur E. Frankel links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 144 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A STING-activating nanovaccine for cancer immunotherapy
Hit paper breakdown →
2017752
2
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Hit paper breakdown →
2017496
3
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
Hit paper breakdown →
2021192
4 2014192
5
Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins.
198594
6 198990
7 199084
8 201981
9 200878
10 198573
11 200770
12 198968
13 199766
14
Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells.
199661
15
Adhesion-dependent multicellular drug resistance.
199959
16
A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia.
198858
17 200557
18 199657
19 198954
20
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
198754

About Arthur E. Frankel

Arthur E. Frankel is a scholar working on Immunology, Biotechnology, Molecular Biology, Oncology and Genetics, having authored 144 papers that have together received 5.2k indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (82 papers), Transgenic Plants and Applications (40 papers), Virus-based gene therapy research (21 papers), Monoclonal and Polyclonal Antibodies Research (21 papers), Cancer Research and Treatments (20 papers), CAR-T cell therapy research (18 papers), Bacillus and Francisella bacterial research (15 papers) and Microbial Inactivation Methods (11 papers). The work is most often cited by research in Biotechnology (1.3k citations), Immunology (2.5k citations), Oncology (1.4k citations), Molecular Biology (2.6k citations) and Cancer Research (495 citations). Arthur E. Frankel has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Andrew Hertler, Eugene P. Frenkel, Andrew Y. Koh, Andrew Thorburn, Yang Xie, Laura Coughlin, Thomas Froehlich, Jiwoong Kim, Ugo Testa and Zhijian J. Chen. Their work appears in journals such as Journal of Clinical Oncology, Blood, Leukemia Research, Molecular Cancer Therapeutics and Bioconjugate Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact